Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck

Cannot have received: anti-cancer monoclonal antibody

prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study day 1

Cannot have received: targeted small molecule therapy

prior targeted small molecule therapy within 2 weeks prior to study day 1

Cannot have received: radiation therapy

radiation therapy within 2 weeks prior to study day 1

Cannot have received: anti-CTLA4 therapy

prior therapy with an anti-CTLA4 agent

Cannot have received: anti-PD-1 therapy

prior therapy with an anti-PD-1 agent

Cannot have received: anti-PD-L1 therapy

prior therapy with an anti-PD-L1 agent

Cannot have received: anti-PD-L2 therapy

prior therapy with an anti-PD-L2 agent

Cannot have received: cell-depleting therapies (CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-CD19, anti-CD20)

Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, some examples include: CAMPATH, anti-CD4, anti-CD5, anti-CD3, anti-Cluster of Differentiation 19 (CD19) and anti-CD20

Cannot have received: alkylating agent (chlorambucil)

Any previous treatment with alkylating agents such as chlorambucil

Cannot have received: total lymphoid irradiation

any previous treatment with total lymphoid irradiation

Cannot have received: tocilizumab (tocilizumab)

Exception: exception may be granted for upon application to the sponsor on a case-by-case basis

Previous treatment with tocilizumab (an exception to this criterion may be granted for upon application to the sponsor on a case-by-case basis)